Although both kinases share substrates (Table 1), the distinct clinical outcome of inactivating mutations indicates they are not functionally redundant, i.e., a disorder within the autism spectrum for DYRK1A and a metabolic syndrome for DYRK1B (abdominal obesity metabolic syndrome-3, OMIM#615812; [93]). This evidence concerns the gene DYRK1A and metabolic syndrome.